Semaglutide trial investigates intestinal barrier function in Short Bowel Syndrome with Intestinal Failure (SBS-IF) patients over 28 days.
Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.
Abstract
A preliminary randomized controlled trial is investigating whether semaglutide 0.25 mg weekly improves intestinal barrier function in SBS-IF patients over 28 days.